Harvard Men's Health Watch

Cheaper treatment for vision loss just as safe as expensive option

An independent review of nine clinical trials found no clear difference in safety between two drugs for age-related vision loss, despite current practice to favor use of the more expensive drug because of safety concerns.
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »